Evidence map›Paper›PMID 32681497›Full record

ReviewImmunologic research2020

COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy.

Carlo Perricone, Elena Bartoloni, Roberto Bursi, Giacomo Cafaro, Giacomo Maria Guidelli, Yehuda Shoenfeld, Roberto Gerli

Open access · hybridAbstract readReview
In one paragraph

Review in Immunologic research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
111citing papers in PubMed, 4 pooled it
24.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

111 citing papers in PubMed, 4 syntheses or guidelines pooled it, 210 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Can iron chelators ameliorate viral infections?Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024
    Review
  11. Review
  12. Article
  13. Article
  14. An overview on in vitro and in vivo antiviral activity of lactoferrin: its efficacy against SARS-CoV-2 infection.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

51 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Carlo PerriconeRheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy.ORCID 0000-0003-4771-6981
Elena BartoloniRheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy.
Roberto BursiRheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy.
Giacomo CafaroRheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy.
Giacomo Maria GuidelliRheumatology and Clinical Immunology Humanitas Research Hospital, Rozzano, Milan, Italy.
Yehuda ShoenfeldZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, 5265601, Tel-Hashomer, Israel.
Roberto GerliRheumatology, Department of Medicine, University of Perugia, Piazzale Giorgio Menghini, 1, 06129, Perugia, Italy. roberto.gerli@unipg.it.
University of Perugia · ITIRCCS Humanitas Research Hospital · ITTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection is characterized by a protean clinical picture that can range from asymptomatic patients to life-threatening conditions. Severe COVID-19 patients often display a severe pulmonary involvement and develop neutrophilia, lymphopenia, and strikingly elevated levels of IL-6. There is an over-exuberant cytokine release with hyperferritinemia leading to the idea that COVID-19 is part of the hyperferritinemic syndrome spectrum. Indeed, very high levels of ferritin can occur in other diseases including hemophagocytic lymphohistiocytosis, macrophage activation syndrome, adult-onset Still's disease, catastrophic antiphospholipid syndrome and septic shock. Numerous studies have demonstrated the immunomodulatory effects of ferritin and its association with mortality and sustained inflammatory process. High levels of free iron are harmful in tissues, especially through the redox damage that can lead to fibrosis. Iron chelation represents a pillar in the treatment of iron overload. In addition, it was proven to have an anti-viral and anti-fibrotic activity. Herein, we analyse the pathogenic role of ferritin and iron during SARS-CoV-2 infection and propose iron depletion therapy as a novel therapeutic approach in the COVID-19 pandemic.

Indexed as

Coronavirus InfectionsIron OverloadPandemicsPneumonia, ViralBetacoronavirusCOVID-19FerritinsHumansIronIron Chelating AgentsSARS-CoV-2FerritinsIronIron Chelating AgentsAdult-onset Still’s diseaseAnti-viralCatastrophic antiphospholipid syndromeCOVID-19DeferoxamineHemophagocytic lymphohistiocytosisHyperferritinemicIronIron depletion therapyMacrophage activation syndromeSARS-CoV-2

Identifiers

PMID32681497
PMCPMC7366458
OpenAlexW3042676445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.